CELULARITY INC

Celularity raises $10M debt to fast‑track placental‑derived cell therapies, aiming for positive cash flow by Q1 2027 and strengthening growth prospects.

Celularity Inc. is pushing the frontier of off‑the‑shelf placental‑derived cell therapies, offering a new path to treat cancer, infections and degenerative diseases while navigating the financial and regulatory challenges of clinical‑stage biotech.

Celularity’s stock drops after CMS pulls reimbursement for its LCD skin‑substitute, but the company’s diversified cell‑therapy pipeline and payer‑engagement strategy aim to offset the loss and drive future revenue growth.